{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T08:32:14Z","timestamp":1786869134231,"version":"build-2736575974"},"reference-count":34,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>There are few reports about the clinical results of proton beam therapy for esophageal cancer in a large population. The purpose of this study was to evaluate the clinical results of proton beam therapy for esophageal cancer in a large population using a multicentered database. Between January 2009 and December 2013, patients newly diagnosed with esophageal cancer and who had received proton beam therapy were retrospectively recruited from a database of four proton beam therapy centers in Japan. Two hundred and two patients (including 90 inoperable patients) fulfilled the inclusion criteria, and 100 patients (49.5%) had stage III\/IV cancer (Union for International Cancer Control 8th). The 3-year and 5-year overall survival rate was 66.7% and 56.3%, respectively. The five-year local control rate was 64.4%. There were two patients with grade three pericardial effusion (1%) and a patient with grade three pneumonia (0.5%). No grade 4 or higher cardiopulmonary toxicities were observed (Common Terminology Criteria for Adverse Events version 4.0). This study suggests that proton beam therapy for esophageal cancer was not inferior in efficacy and had lower rates of toxicities in comparison to photon radiotherapy. Therefore, proton beam therapy can serve as an alternate treatment for patients with esophageal cancer.<\/jats:p>","DOI":"10.3390\/cancers11070993","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T02:44:03Z","timestamp":1563331443000},"page":"993","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Clinical Results of Proton Beam Therapy for Esophageal Cancer: Multicenter Retrospective Study in Japan"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9711-1158","authenticated-orcid":false,"given":"Takashi","family":"Ono","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, QST Hospital, 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba 263-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Southern Tohoku Proton Therapy Center 7-172, Yatsuyamada, Koriyama, Fukushima 963-8052, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-9787","authenticated-orcid":false,"given":"Hitoshi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1, Amakubo, Tsukuba, Ibaraki 305-8576, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Tamamura","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Proton Therapy Center, FukuiPrefectural Hospital, 2-8-1, Yotsui, Fukui-shi, Fukui-ken 910-8526, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunao","family":"Tokumaru","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hyogo Ion Beam Medical Center, 1-2-1, Koto, Shingu-cho, Tatsuno City, Hyogo 679-5165, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","article-title":"The global burden of cancer 2013","volume":"1","author":"Fitzmaurice","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10388-017-0578-4","article-title":"Comprehensive registry of esophageal cancer in Japan, 2010","volume":"14","author":"Tachimori","year":"2017","journal-title":"Esophagus"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","article-title":"A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)","volume":"19","author":"Ando","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01)","volume":"281","author":"Cooper","year":"1999","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","article-title":"INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy","volume":"20","author":"Minsky","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/jjco\/hyp069","article-title":"A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708)","volume":"39","author":"Kato","year":"2009","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ijrobp.2010.06.033","article-title":"Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906)","volume":"81","author":"Kato","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.radonc.2008.12.012","article-title":"A randomized phase II study of cisplatin\/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101\/JROSG021)","volume":"92","author":"Nishimura","year":"2009","journal-title":"Radiother. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0360-3016(98)00047-9","article-title":"Comparative treatment planning between proton and x-ray therapy in esophageal cancer","volume":"41","author":"Isacsson","year":"1998","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijrobp.2008.05.014","article-title":"Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer","volume":"72","author":"Zhang","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2017.07.034","article-title":"Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy","volume":"125","author":"Shiraishi","year":"2017","journal-title":"Radiother. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/jrr\/rrv001","article-title":"Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis","volume":"56","author":"Makishima","year":"2015","journal-title":"J. Radiat. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13014-018-0966-5","article-title":"Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma","volume":"13","author":"Hirano","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.14338\/IJPT.14-editorial-2.1","article-title":"Particle therapy statistics in 2013","volume":"1","author":"Jermann","year":"2014","journal-title":"Int. J. Particle Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/jjco\/hyw102","article-title":"Proton beam therapy in Japan: Current and future status","volume":"46","author":"Sakurai","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_17","first-page":"3571","article-title":"Proton beam therapy with high-dose irradiation for superficial and advanced esophageal carcinomas","volume":"9","author":"Shohei","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijrobp.2004.04.003","article-title":"Clinical results of proton beam therapy for cancer of the esophagus","volume":"61","author":"Sugahara","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1016\/j.ijrobp.2011.02.041","article-title":"Hyperfractionated concomitant boost proton beam therapy for esophageal carcinoma","volume":"81","author":"Mizumoto","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1515\/raon-2015-0034","article-title":"Clinical results of proton beam therapy for twenty older patients with esophageal cancer","volume":"49","author":"Ono","year":"2015","journal-title":"Radiol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/j.ijrobp.2012.01.003","article-title":"Proton beam therapy and concurrent chemotherapy for esophageal cancer","volume":"83","author":"Lin","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_22","first-page":"1757","article-title":"Proton beam therapy combined with concurrent chemotherapy for esophageal cancer","volume":"35","author":"Ishikawa","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cam4.607","article-title":"Preliminary treatment results of proton beam therapy with chemoradiotherapy for stage I-III esophageal cancer","volume":"5","author":"Takada","year":"2016","journal-title":"Cancer Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s10147-015-0896-2","article-title":"Chemoradiotherapy for T4 and\/or M1 lymph node esophageal cancer: Experience since 2000 at a high-volume center in Japan","volume":"21","author":"Jingu","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2017.06.2450","article-title":"Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: A retrospective, single-institutional analysis","volume":"99","author":"Xi","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/jjco\/hyu047","article-title":"High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer","volume":"44","author":"Suh","year":"2014","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2004.06.022","article-title":"Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy","volume":"61","author":"Zhang","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.radonc.2006.01.009","article-title":"Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response","volume":"78","author":"Geh","year":"2006","journal-title":"Radiother. Oncol."},{"key":"ref_29","first-page":"516","article-title":"Increased risk of death due to heart disease after radiotherapy for esophageal cancer","volume":"6","author":"Frandsen","year":"2015","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"20140168","DOI":"10.1259\/bjr.20140168","article-title":"Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy","volume":"88","author":"Hayashi","year":"2015","journal-title":"Br. J. Radiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.radonc.2010.02.006","article-title":"Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer","volume":"95","author":"Asakura","year":"2010","journal-title":"Radiother. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/jrr\/rrt047","article-title":"Dose-volume analysis for respiratory toxicity in intrathoracic esophageal cancer patients treated with definitive chemoradiotherapy using extended fields","volume":"54","author":"Tanabe","year":"2013","journal-title":"J. Radiat. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/annonc\/mdn622","article-title":"Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis","volume":"20","author":"Bollschweiler","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_34","unstructured":"(2018, January 25). Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, Available online: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5\u00d711.pdf."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/7\/993\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:06:18Z","timestamp":1760187978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/7\/993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,16]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["cancers11070993"],"URL":"https:\/\/doi.org\/10.3390\/cancers11070993","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,16]]}}}